Konference: 2016 XL. Brněnské onkologické dny a XXX. Konference pro nelékařské zdravotnické pracovníky
Téma: XXXII. Základní a aplikovaný výzkum v onkologii
Číslo abstraktu: XXXII/220
Autoři: Bc. Monika Vahalíková; MUDr. Josef Srovnal, Ph.D.; Mgr. Andrea Prokopová; Ing. Soňa Gurská, Ph.D.; Alona Chasovskykh; Mgr. Jana Vrbková, Ph.D.; doc. MUDr. Marián Hajdúch, Ph.D.
Introduction:
Pancreatic and colorectal cancer (CRC) is the most common cause of death from cancer in the world. These tumors are also known for their high incidence of metastases. In our previous study we analyzed the presence of circulating tumor cells (CTCs) in two groups of CRC and pancreatic cancer patients. One group received morphine analgesia (MA) and second piritramide analgesia (PA). We found that MA in patients with CRC is associated with increased numbers of CTCs and is associated with significantly shorter disease-free survival (DFS). Opposite effect of MA was observed in pancreatic cancer. Patients with MA had significantly longer overall survival (OS) and DFS than patients with PA. The aim of this study was to analyze opioid receptors expression in the tumor tissue samples of cancer patients and clarify its influence on survival.
Materials and Methods:
The expression of opioid receptors was tested in tissue samples from 146 patients with CRC and 101 patients with pancreatic cancer. Expression of opioid receptors μ, δ, κ and opioid growth factor receptor was detected using real-time RT-PCR on LightCycler 1536 from Roche. For data analysis was used relative quantification concretely ΔΔCt method.
Results:
The expression of opioid receptors was compared between cancers and between various stages in CRC and the various stages of surgery radicality in pancreatic cancer. We found no significant difference in expression of opioid receptors between stages. When we compared expression of opioid receptors in CRC and pancreatic cancer, we found that in pancreatic cancer is forty times higher expression of opioid receptor μ than in CRC.
Conclusion:
In pancreatic and colorectal cancer is no significant difference in expression of opioid receptors between stages. In pancreatic cancer is higher expression of opioid receptor μ than in CRC. It can be cause of the difference of influence of morphine analgesia on DFS and OS in patients with pancreatic and colorectal cancer.
The work was supported by grants IGA LF UP 2016_010, TACR TE02000058 and NPU L01304.
Datum přednesení příspěvku: 28. 4. 2016
